Mark Hutchins

1.0k total citations
15 papers, 760 citations indexed

About

Mark Hutchins is a scholar working on Pathology and Forensic Medicine, Genetics and Immunology. According to data from OpenAlex, Mark Hutchins has authored 15 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 7 papers in Genetics and 4 papers in Immunology. Recurrent topics in Mark Hutchins's work include Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Mark Hutchins is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Mark Hutchins collaborates with scholars based in United States, United Kingdom and Germany. Mark Hutchins's co-authors include Scot Sorensen, D F Moravec, Jamés O. Armitage, Monroe D. Dowling, David Howe, Philip J. Bierman, J A Mailliard, Dennis D. Weisenburger, Julie M. Vose and S Eto and has published in prestigious journals such as Journal of Clinical Oncology, The American Journal of Medicine and BioScience.

In The Last Decade

Mark Hutchins

15 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Hutchins United States 11 479 248 169 153 102 15 760
Richard B. Marshall United States 23 202 0.4× 334 1.3× 79 0.5× 61 0.4× 417 4.1× 44 1.5k
Gertrud E. B. Berg Sweden 18 351 0.7× 109 0.4× 112 0.7× 51 0.3× 83 0.8× 39 1.6k
Leah Katz United States 11 91 0.2× 217 0.9× 253 1.5× 319 2.1× 304 3.0× 33 1.1k
Esther Alfandary Israel 9 77 0.2× 209 0.8× 207 1.2× 297 1.9× 274 2.7× 11 1.2k
Clara Ruíz-Ponte Spain 17 621 1.3× 319 1.3× 71 0.4× 81 0.5× 100 1.0× 52 1.2k
A. Moretti Italy 18 86 0.2× 67 0.3× 65 0.4× 160 1.0× 93 0.9× 32 1.5k
Richard R. Blough United States 15 233 0.5× 284 1.1× 87 0.5× 185 1.2× 272 2.7× 40 1.5k
Kiyoto Ashizawa Japan 22 192 0.4× 200 0.8× 51 0.3× 46 0.3× 139 1.4× 51 1.6k
Jeong Soo Kim South Korea 22 115 0.2× 298 1.2× 49 0.3× 28 0.2× 174 1.7× 128 1.4k

Countries citing papers authored by Mark Hutchins

Since Specialization
Citations

This map shows the geographic impact of Mark Hutchins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Hutchins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Hutchins more than expected).

Fields of papers citing papers by Mark Hutchins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Hutchins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Hutchins. The network helps show where Mark Hutchins may publish in the future.

Co-authorship network of co-authors of Mark Hutchins

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Hutchins. A scholar is included among the top collaborators of Mark Hutchins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Hutchins. Mark Hutchins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Chemaly, Roy F., Monica K Sikka, Mary K. Hayden, et al.. (2011). Serratia marcescens bacteremia because of contaminated prefilled heparin and saline syringes: A multi-state report. American Journal of Infection Control. 39(6). 521–524. 17 indexed citations
3.
Soori, Gamini S., et al.. (2008). A prospective study of patient accrual to clinical trials at a NCI-funded Community Clinical Oncology Program. Journal of Clinical Oncology. 26(15_suppl). 9610–9610. 1 indexed citations
4.
Copur, Mehmet Sitki, et al.. (2004). An Unusual Case of Composite Lymphoma Involving Chronic Lymphocytic Leukemia Follicular Lymphoma and Hodgkin Disease. Leukemia & lymphoma. 45(5). 1071–1076. 11 indexed citations
5.
Irland, Lloyd C., Darius M. Adams, Ralph J. Alig, et al.. (2001). Assessing Socioeconomic Impacts of Climate Change on US Forests, Wood-Product Markets, and Forest Recreation. BioScience. 51(9). 753–753. 69 indexed citations
6.
7.
Bierman, Philip J., Phyllis I. Warkentin, Mark Hutchins, & Lynell W. Klassen. (1993). Pure Red Cell Aplasia Following ABO Mismatched Marrow Transplantation for Chronic Lymphocytic Leukemia: Response to Antithymocyte Globulin. Leukemia & lymphoma. 9(1-2). 169–171. 17 indexed citations
8.
Vose, Julie M., P. J. Bierman, J R Anderson, et al.. (1991). CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity.. Journal of Clinical Oncology. 9(8). 1421–1425. 20 indexed citations
9.
Armitage, Jamés O., Philip J. Bierman, Dennis D. Weisenburger, et al.. (1989). Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. The American Journal of Medicine. 87(3). 285–288. 44 indexed citations
10.
Armitage, Jamés O., Julie M. Vose, J Linder, et al.. (1989). Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 7(12). 1783–1790. 76 indexed citations
11.
Vose, Julie M., DD Weisenburger, D F Moravec, et al.. (1988). Ch1VPP—An Effective and Well-Tolerated Alternative to MOPP Therapy for Hodgkinʼs Disease. American Journal of Clinical Oncology. 11(4). 423–426. 14 indexed citations
12.
Vose, Julie M., Jamés O. Armitage, Dennis D. Weisenburger, et al.. (1988). The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 6(12). 1838–1844. 225 indexed citations
13.
Armitage, Jamés O., DD Weisenburger, Mark Hutchins, et al.. (1986). Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.. Journal of Clinical Oncology. 4(2). 160–164. 132 indexed citations
14.
Hutchins, Mark, et al.. (1985). Abnormal immunoregulation in remission Hodgkin disease. American Journal of Hematology. 20(2). 119–128. 2 indexed citations
15.
Eto, S, J.M. Wood, Mark Hutchins, & N Fleischer. (1974). Pituitary 45 Ca ion uptake and release of ACTH, GH, and TSH: effect of verapamil. American Journal of Physiology-Legacy Content. 226(6). 1315–1320. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard B. Marshall Breakdown of academic impact, for papers by Gertrud E. B. Berg Breakdown of academic impact, for papers by Leah Katz Breakdown of academic impact, for papers by Esther Alfandary Breakdown of academic impact, for papers by Clara Ruíz-Ponte Breakdown of academic impact, for papers by A. Moretti Breakdown of academic impact, for papers by Richard R. Blough Breakdown of academic impact, for papers by Kiyoto Ashizawa Breakdown of academic impact, for papers by Jeong Soo Kim
Rankless by CCL
2026